Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN

Liu,Jun; Tong,Shi‑Jun; Wang,Xiang; Qu,Lian‑Xi

doi:10.3892/etm.2014.1894

Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN

Authors:
- Jun Liu
- Shi‑Jun Tong
- Xiang Wang
- Lian‑Xi Qu
View Affiliations

Affiliations: Department of Urology Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China
Published online on: August 11, 2014 https://doi.org/10.3892/etm.2014.1894
Pages: 1209-1212

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. In the present study, the activation of the farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, was demonstrated to inhibit cell proliferation in LNcaP cells. Using clinical samples, mRNA and protein levels of FXR were found to be significantly decreased by quantitative PCR and western blot analysis in prostate cancer tissues. In vitro studies identified further that activation or overexpression of FXR suppressed prostate cancer cell proliferation as measured by BrdU incorporation assays. At the molecular level, the results further revealed that the expression of the tumor suppressor gene, PTEN, was upregulated by FXR activation. Therefore, the observations indicated that FXR functions as a tumor suppressor in prostate cancer, which may provide a novel method for molecular targeting cancer treatment.

View Figures

View References

1	Makishima M, Okamoto AY, Repa JJ, et al: Identification of a nuclear receptor for bile acids. Science. 284:1362–1365. 1999. View Article : Google Scholar : PubMed/NCBI
2	Urizar NL, Liverman AB, Dodds DT, et al: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 296:1703–1706. 2002. View Article : Google Scholar : PubMed/NCBI
3	Hollman DA, Milona A, van Erpecum KJ and van Mil SW: Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta. 1821:1443–1452. 2012. View Article : Google Scholar : PubMed/NCBI
4	Matsubara T, Li F and Gonzalez FJ: FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 368:17–29. 2013. View Article : Google Scholar : PubMed/NCBI
5	Porez G, Prawitt J, Gross B and Staels B: Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 53:1723–1737. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G and Gonzalez FJ: Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 102:731–744. 2000. View Article : Google Scholar : PubMed/NCBI
7	Gardmo C, Tamburro A, Modica S and Moschetta A: Proteomics for the discovery of nuclear bile acid receptor FXR targets. Biochim Biophys Acta. 1812:836–841. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kemper JK: Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta. 1812:842–850. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lu Y, Ma Z, Zhang Z, et al: Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut. 63:170–178. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yang F, Huang X, Yi T, Yen Y, Moore DD and Huang W: Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67:863–867. 2007. View Article : Google Scholar : PubMed/NCBI
11	Modica S, Murzilli S, Salvatore L, Schmidt DR and Moschetta A: Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 68:9589–9594. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kim I, Morimura K, Shah Y, Yang Q, Ward JM and Gonzalez FJ: Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 28:940–946. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chen Y, Song X, Valanejad L, et al: Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology. 57:1530–1541. 2013. View Article : Google Scholar : PubMed/NCBI
14	Duran-Sandoval D, Mautino G, Martin G, et al: Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 53:890–898. 2004. View Article : Google Scholar : PubMed/NCBI
15	Kim MS, Shigenaga J, Moser A, Feingold K and Grunfeld C: Repression of farnesoid X receptor during the acute phase response. J Biol Chem. 278:8988–8995. 2003. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Gong W, Dai S, et al: Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res. 10:516–522. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ohno T, Shirakami Y, Shimizu M, et al: Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand. Cancer Lett. 323:215–222. 2012. View Article : Google Scholar : PubMed/NCBI
18	He N, Park K, Zhang Y, Huang J, Lu S and Wang L: Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology. 134:793–802. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Xu P, Park K, Choi Y, Moore DD and Wang L: Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology. 48:289–298. 2008. View Article : Google Scholar
20	Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
21	Warde N: Prostate cancer: loss of PTEN promotes progression of prostate cancer in an androgen-independent manner. Nat Rev Urol. 8:4122011. View Article : Google Scholar : PubMed/NCBI